Cadila Healthcare's US arm receives FDA nod to market Pimavanserin capsule

The approval by the US Food & Drug Administration for the generic Pimavanserin capsules is for the strength of 34 mg, Cadila Healthcare said in a regulatory filing. "The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad," it said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3pH2XIP
via IFTTT